Hallucinogens - PubMed (original) (raw)
Review
Hallucinogens
David E Nichols. Pharmacol Ther. 2004 Feb.
Abstract
Hallucinogens (psychedelics) are psychoactive substances that powerfully alter perception, mood, and a host of cognitive processes. They are considered physiologically safe and do not produce dependence or addiction. Their origin predates written history, and they were employed by early cultures in a variety of sociocultural and ritual contexts. In the 1950s, after the virtually contemporaneous discovery of both serotonin (5-HT) and lysergic acid diethylamide (LSD-25), early brain research focused intensely on the possibility that LSD or other hallucinogens had a serotonergic basis of action and reinforced the idea that 5-HT was an important neurotransmitter in brain. These ideas were eventually proven, and today it is believed that hallucinogens stimulate 5-HT(2A) receptors, especially those expressed on neocortical pyramidal cells. Activation of 5-HT(2A) receptors also leads to increased cortical glutamate levels presumably by a presynaptic receptor-mediated release from thalamic afferents. These findings have led to comparisons of the effects of classical hallucinogens with certain aspects of acute psychosis and to a focus on thalamocortical interactions as key to understanding both the action of these substances and the neuroanatomical sites involved in altered states of consciousness (ASC). In vivo brain imaging in humans using [(18)F]fluorodeoxyglucose has shown that hallucinogens increase prefrontal cortical metabolism, and correlations have been developed between activity in specific brain areas and psychological elements of the ASC produced by hallucinogens. The 5-HT(2A) receptor clearly plays an essential role in cognitive processing, including working memory, and ligands for this receptor may be extremely useful tools for future cognitive neuroscience research. In addition, it appears entirely possible that utility may still emerge for the use of hallucinogens in treating alcoholism, substance abuse, and certain psychiatric disorders.
Similar articles
- Psychedelics.
Nichols DE. Nichols DE. Pharmacol Rev. 2016 Apr;68(2):264-355. doi: 10.1124/pr.115.011478. Pharmacol Rev. 2016. PMID: 26841800 Free PMC article. Review. - Hallucinogens, serotonin and obsessive-compulsive disorder.
Delgado PL, Moreno FA. Delgado PL, et al. J Psychoactive Drugs. 1998 Oct-Dec;30(4):359-66. doi: 10.1080/02791072.1998.10399711. J Psychoactive Drugs. 1998. PMID: 9924841 Review. - Cellular mechanisms of serotonin 5-HT2A receptor-mediated cGMP formation: the essential role of glutamate.
Regina MJ, Bucelli RC, Winter JC, Rabin RA. Regina MJ, et al. Brain Res. 2004 Apr 2;1003(1-2):168-75. doi: 10.1016/j.brainres.2004.01.014. Brain Res. 2004. PMID: 15019576 - Animal models of obsessive-compulsive disorder: rationale to understanding psychobiology and pharmacology.
Korff S, Harvey BH. Korff S, et al. Psychiatr Clin North Am. 2006 Jun;29(2):371-90. doi: 10.1016/j.psc.2006.02.007. Psychiatr Clin North Am. 2006. PMID: 16650714 Review. - In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems.
Meltzer HY, Huang M. Meltzer HY, et al. Prog Brain Res. 2008;172:177-97. doi: 10.1016/S0079-6123(08)00909-6. Prog Brain Res. 2008. PMID: 18772033 Review.
Cited by
- Novel psychoactive substances of interest for psychiatry.
Schifano F, Orsolini L, Duccio Papanti G, Corkery JM. Schifano F, et al. World Psychiatry. 2015 Feb;14(1):15-26. doi: 10.1002/wps.20174. World Psychiatry. 2015. PMID: 25655145 Free PMC article. - Microdosing psychedelics and the risk of cardiac fibrosis and valvulopathy: Comparison to known cardiotoxins.
Rouaud A, Calder AE, Hasler G. Rouaud A, et al. J Psychopharmacol. 2024 Mar;38(3):217-224. doi: 10.1177/02698811231225609. Epub 2024 Jan 12. J Psychopharmacol. 2024. PMID: 38214279 Free PMC article. Review. - Powerful substances in tiny amounts: An interview study of psychedelic microdosing.
Johnstad PG. Johnstad PG. Nordisk Alkohol Nark. 2018 Feb;35(1):39-51. doi: 10.1177/1455072517753339. Epub 2018 Feb 15. Nordisk Alkohol Nark. 2018. PMID: 32934512 Free PMC article. - Recreational use, analysis and toxicity of tryptamines.
Tittarelli R, Mannocchi G, Pantano F, Romolo FS. Tittarelli R, et al. Curr Neuropharmacol. 2015 Jan;13(1):26-46. doi: 10.2174/1570159X13666141210222409. Curr Neuropharmacol. 2015. PMID: 26074742 Free PMC article. Review. - Chemogenomics knowledgebase and systems pharmacology for hallucinogen target identification-Salvinorin A as a case study.
Xu X, Ma S, Feng Z, Hu G, Wang L, Xie XQ. Xu X, et al. J Mol Graph Model. 2016 Nov;70:284-295. doi: 10.1016/j.jmgm.2016.08.001. Epub 2016 Aug 8. J Mol Graph Model. 2016. PMID: 27810775 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous